Protagenic Therapeutics, Inc. (PTIXW)

US — Healthcare Sector
Peers: ENSCW  HLVX  PTIX  THRD  IINNW 

Automate Your Wheel Strategy on PTIXW

With Tiblio's Option Bot, you can configure your own wheel strategy including PTIXW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PTIXW
  • Rev/Share -0.0068
  • Book/Share -1.0737
  • PB -3.1666
  • Debt/Equity -1.0098
  • CurrentRatio 0.414
  • ROIC -156.0955

 

  • MktCap 2952608.0
  • FreeCF/Share -0.8756
  • PFCF -0.9111
  • PE -1.4477
  • Debt/Assets 0.6185
  • DivYield 0
  • ROE 14.9216

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Protagenic Therapeutics, Inc. (PTIXW)

  • IPO Date 2021-04-27
  • Website http://www.protagenic.com
  • Industry Biotechnology
  • CEO Garo H. Armen
  • Employees 1
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.